Show simple item record

dc.contributor.authorLópez-Villar, Elena
dc.contributor.authorMartos Moreno, Gabriel Ángel 
dc.contributor.authorChowen, Julie Ann
dc.contributor.authorOkada, Shigeru
dc.contributor.authorKopchick, John J.
dc.contributor.authorArgente Oliver, Jesús 
dc.contributor.otherUAM. Departamento de Pediatríaes_ES
dc.contributor.otherInstituto de Investigación del Hospital de La Princesa (IP)es_ES
dc.date.accessioned2016-07-28T13:39:11Z
dc.date.available2016-07-28T13:39:11Z
dc.date.issued2015-01-01
dc.identifier.citationJournal of Cellular and Molecular Medicine 19.7 (2015): 1455-1470en_US
dc.identifier.issn1582-1838es_ES
dc.identifier.issn1582-4934 (on line)es_ES
dc.identifier.urihttp://hdl.handle.net/10486/672290
dc.description.abstractThe incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However, the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceutical communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes areaen_US
dc.description.sponsorshipThis work is funded by Ministerio de Ciencia e Innovación (BFU2011–27492), Fondos de Investigación Sanitaria (PI1302195), Centro de Investigación Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III and Fundación de Endocrinología y Nutrición. Dr. Elena López Villar is supported by ISCIII Spanish Health System (SNS BOE 2012) and she is Delegate of HUPO (Human Proteome Organization) supporting clinical proteomic studies at Hospital Niño Jesús of Madrid, Spain, to improve diagnosis and therapies via researchen_US
dc.format.extent16 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherJohn Wiley & Sons Ltd.en_US
dc.publisherFoundation for Cellular and Molecular Medicineen_US
dc.relation.ispartofJournal of Cellular and Molecular Medicineen_US
dc.rights© 2015 The Authorsen_US
dc.subject.otherBiomarkersen_US
dc.subject.otherDiabetes mellitus type 2en_US
dc.subject.otherObesityen_US
dc.subject.otherProteomicsen_US
dc.titleA proteomic approach to obesity and type 2 diabetesen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1111/jcmm.12600es_ES
dc.identifier.doi10.1111/jcmm.12600es_ES
dc.identifier.publicationfirstpage1455es_ES
dc.identifier.publicationissue7es_ES
dc.identifier.publicationlastpage1470es_ES
dc.identifier.publicationvolume19es_ES
dc.relation.projectIDGobierno de España. BFU2011–27492es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.authorUAMArgente Oliver, Jesús (100008)
dc.authorUAMChowen , Julie Ann (268961)
dc.authorUAMMartos Moreno, Gabriel Ángel (101491)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record